Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WIN Symposium 2018 /
Early development in oncology: Are the MTD and monotherapy efficacy still the best objectives?

25th - 26th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.07.18
Views: 1040

Dr Giorgio Massimini - Merck KGaA, Germany

Dr Massimini speaks with ecancer at the 2018 WIN Symposium about drug development and whether we should still be aiming at maximum tolerability dose.

He suggests another endpoint could be the biological effective dose, when the dosage amount gives the best biological effect on the target.

Dr Massimini finally outlines the MERCURY trial which is an evolution of several other trials, and which will play close attention to the level of expression of the target in the normal tissue.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation